This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysis Of The U.S. Neurostimulation Market

 

 

 

NEW YORK, March 25, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Analysis of the U.S. Neurostimulation Market http://www.reportlinker.com/p01099851/Analysis-of-the-US-Neurostimulation-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_EquipmentThis research service looks at the neurostimulation devices market in the United States. The market is expected to see many technology advancements in the next decade. Therefore, a thorough understanding of revenue forecasts, unit forecasts, technological advances, and pricing analyses are provided for the market's various segments including: spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, and sacral nerve stimulators. Furthermore, market engineering measurements, industry challenges, drivers, restraints, company profiling, product profiling, and technology trends are covered along with an analysis of the market's highly competitive landscape. The base year is 2012; the forecast period extends through 2018.

Executive Summary•The size of the total neurostimulation market was estimated to be $X million in 2012 and is projected to grow at a compound annual growth rate (CAGR) of X percent over the next seven years, to reach $X million in 2018.•In 2012, the total revenue generated by sales of neurostimulator devices in the United States was estimated to represent X percent increase over 2011 revenue.•Competitors generating the highest revenue in the U.S. neurostimulation market in 2012 were Medtronic, St. Jude Medical, Boston Scientific Corp., and Cyberonics. Together, they were estimated to contribute Xpercent of total market revenue.•The Spinal Cord Stimulators (SCS) market is the largest neurostimulation segment, constituting X percent of the U.S. neurostimulation market and likely to grow at a significant CAGR of X per between 2012 and 2018.•In 2012, the other neurostimulation segments, including Deep Brain Stimulators (DBS), Vagus Nerve Stimulators (VNS), and Sacral Nerve Stimulators (SNS), were estimated to contribute Xpercent, Xpercent, andXpercent respectively.•In 2012, an estimated X neurostimulator implant procedures were performed in the United States.•Neurostimulator implant procedures are projected to grow at a CAGR of X percent from 2012 to 2018, reaching X in 2018.•The rising prevalence of diseases, growing demand for new alternative therapies to meet the demands of unmet clinical needs, and an aging baby-boomer population in the United States are likely to drive growth in the market.•However, regulatory approvals and insurance reimbursement pose major challenges for neurostimulator manufacturers in the United States.•Market participants may need to focus on developing disruptive technologies to further enhance the product or the technology adoption rate.

TABLE OF CONTENTS Executive Summary 5Market Overview 10Total Neurostimulation Market 18•Industry Challenges 20•External Challenges: Drivers and Restraints 26•Forecasts and Trends 34•Demand Analysis 43•Market Share and Competitive Analysis 46Strategic Pipeline Assessment 57Company Profiles and Industry Highlights of Top Neurostimulation Market Participants 62Segment Analysis 74•Spinal Cord Stimulators Segment Breakdown 77•Deep Brain Stimulators Segment Breakdown 103•Vagus Nerve Stimulators Segment Breakdown 129•Sacral Nerve Stimulators Segment Breakdown 153Strategic Recommendations and Conclusions 180The Last Word 185Appendix 188

To order this report:: Analysis of the U.S. Neurostimulation Market

__________________________Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs